Strategic indicators tracking Biovac's contribution to Africa's vaccine future — manufacturing capacity expansion, economic impact, and skills development aligned with NDP 2030, AU Agenda 2063, and PAVM targets.
Biovac sits at the intersection of three policy mandates. Click or hover each circle to explore how our operations align with national, continental, and global targets.
Eliminating Africa's dependency on imported vaccines. Scaling from 150M to 560M annual doses through end-to-end manufacturing — Drug Substance through to Fill & Finish — at the Pinelands facility and future expansion sites.
NDP 2030End-to-end vaccine manufacturing capability on the African continent. R800M+ invested in infrastructure, R500M+ annual economic impact, and a growing SADC distribution network delivering affordable vaccines across the region.
AU 2063 / PAVM400+ employees, 85% with tertiary education. Three completed international technology transfers (Pfizer, Sanofi, WHO mRNA Hub). Building a deep bench of African biotech talent through training programs and university partnerships.
WHO IA2030In partnership with the International Vaccine Institute (IVI), Biovac is becoming the first African manufacturer to produce oral cholera vaccine from drug substance to finished product — a landmark in continental vaccine self-sufficiency.
African DS manufacturer
Target WHO PQ
As a spoke partner of the WHO mRNA Technology Transfer Hub, Biovac collaborates with Afrigen Biologics to build continental mRNA manufacturing capability — enabling rapid-response vaccine production for future pandemics and endemic diseases.
Platform capability
Hub co-manufacturer
Join us in building South Africa's vaccine manufacturing capability. Whether you bring technology, capital, or expertise — there is a role for you in this national transformation.